Form 4: ClearPoint Neuro Director Linda M. Liau Acquires Shares in Lieu of Fees
SEC Form 4 Filing
Director Linda M. Liau acquired 193 shares of ClearPoint Neuro, Inc. common stock on January 2, 2025, as payment for director fees.
Summary
- On January 2, 2025, Linda M. Liau, a director of ClearPoint Neuro, Inc., acquired 193 shares of common stock.
- The shares were issued as payment for fees owed to Liau under the company's Non-Employee Director Compensation Plan.
- The price per share was $15.38, based on the closing price of ClearPoint Neuro's common stock on December 31, 2024.
- Following the transaction, Liau directly owns 31,291 shares of ClearPoint Neuro, Inc.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction. It's neutral to slightly positive as it shows director commitment but doesn't contain significant news.
Positives
- The acquisition of shares by a director demonstrates confidence in the company.
- Using shares to pay director fees conserves the company's cash resources.
Industry Context
Director share acquisitions are common and can be seen as a positive signal, indicating confidence in the company's future prospects. Paying directors with shares is also a common practice, especially for smaller companies, as it helps conserve cash.
Comparison to Industry Standards
- Director compensation through stock awards is a common practice among publicly traded companies, particularly in the biotech and medical device sectors.
- The amount of stock awarded to directors varies widely based on company size, performance, and industry norms.
- Comparing ClearPoint Neuro's director compensation plan to those of similar-sized companies in the neurotech space would provide a more detailed benchmark.
Related Party Transactions
- The issuance of shares to Linda M. Liau, a director, in lieu of cash compensation is a related party transaction.
Stakeholder Impact
- The transaction has a minimal impact on shareholders, as it involves a small number of shares issued as compensation.
- Employees are indirectly impacted as the company conserves cash by issuing shares instead of cash compensation.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date used to determine the share price for the transaction. |
| 01/02/2025 | Date of the transaction (share acquisition). |
| 01/03/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.